Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines

Manuela Lemoine, Enrico Derenzini, Daniela Buglio, L. Jeffrey Medeiros, R. Eric Davis, Jiexin Zhang, Yuan Ji, Anas Younes

Blood (2012) 119 (17): 4017–4025.

https://doi.org/10.1182/blood-2011-01-331421

Published: 2012

Includes: Supplemental data

Journal Articles

Safety and Efficacy of the Novel Combination of Panobinostat (LBH589) and Everolimus (RAD001) in Relapsed/Refractory Hodgkin and Non-Hodgkin Lymphoma,

Anas Younes, MD, Amanda Copeland, MSN, Michelle A. Fanale, MD, Luis Fayad, MD, Jorge E Romaguera, MD, Larry W Kwak, MD, PhD, Sattva S. Neelapu, MD, Fredrick Hagemeister, MD, Barbara Pro, MD, Silvana de Castro Faria, MD, Yuan Ji, PhD, Donald Berry, Daniela Buglio, MD, PhD, L. Jeffrey Medeiros, MD

Blood (2011) 118 (21): 3718.

https://doi.org/10.1182/blood.V118.21.3718.3718

Published: 2011

Journal Articles

Combined Inhibition of Janus and Aurora Kinases by the Novel Small Molecule Inhibitor AZD1480 Induces Cell Death and Downregulates PD-L1 and PD-L2 Expression In Hodgkin Lymphoma

Enrico Derenzini, MD, Daniela Buglio, MD, PhD, Hiroshi Katayama, PhD, Yuan Ji, PhD, Subrata Sen, PhD, Anas Younes, MD

Blood (2010) 116 (21): 2848.

https://doi.org/10.1182/blood.V116.21.2848.2848

Published: 2010

Journal Articles

Inhibition of Tak-1 by AZ-Tak1 Impairs NF-κB Activation, Downregulates XIAP and Activates Caspase-9 Inducing Apoptosis In Mantle Cell lymphoma

Daniela Buglio, MD, PhD, Sangeetha Palakurti, PhD, Francisco Vega, PhD, Sattva S. Neelapu, Donald Berry, PhD, Yuan Ji, PhD, Kate Byth, PhD, Anas Younes, MD

Blood (2010) 116 (21): 2852.

https://doi.org/10.1182/blood.V116.21.2852.2852

Published: 2010

Journal Articles

Phase I/II Study of the Novel Combination of Panobinostat (LBH589) and Everolimus (RAD001) In Relapsed/Refractory Hodgkin and Non-Hodgkin Lymphoma

Anas Younes, MD, Amanda Copeland, MSN, Michelle A. Fanale, MD, Fredrick Hagemeister, MD, Luis Fayad, MD, Barbara Pro, MD, Silvana C. Faria, MD, PhD, Yuan Ji, PhD, L. Jeffrey Medeiros, MD, Donald A Berry, PhD, Daniela Buglio, MD, PhD

Blood (2010) 116 (21): 3964.

https://doi.org/10.1182/blood.V116.21.3964.3964

Published: 2010

Journal Articles

A Phase I Study of Bortezomib in Combination with ICE (BICE) in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma

Michelle A. Fanale, M.D., Luis E. Fayad, M.D., Barbara Pro, M.D., Felipe Samaniego, M.D., Gracy Zachariah, R.N., Cesar A. Nunez, M.D., Yuan Ji, Ph.D., Anas Younes, M.D.

Blood (2008) 112 (11): 3048.

https://doi.org/10.1182/blood.V112.11.3048.3048

Published: 2008

Journal Articles

Higher Incidence of Venous Thromboembolism Is Associated with Initial Cycles of Chemotherapy in Lymphoma Patients: Creatinine and Hemoglobin as Key Risk Factors.

Xiao Zhou, MD, Auris Huen, Pharm, Shyam Teegala, MD, Yuan Ji, MD, Luis Fayad, MD, F.B. Hagemeister, MD, Saroj Vadhan-Raj, MD

Blood (2007) 110 (11): 3993.

https://doi.org/10.1182/blood.V110.11.3993.3993

Published: 2007

Journal Articles

Safety and Efficacy of Bortezomib Plus ICE (BICE) for the Treatment of Relapsed/Refractory Classical Hodgkin’s Lymphoma.

Michelle A. Fanale, MD, Luis Fayad, MD, Barbara Pro, MD, Felipe Samaniego, MD, Gracy Zachariah, RN, Cesar A. Nunez, MD, Yuan Ji, PhD, Anas Younes, MD

Blood (2007) 110 (11): 4506.

https://doi.org/10.1182/blood.V110.11.4506.4506

Published: 2007

Journal Articles

High Incidence of Venous Thromboembolism in Patients with Lymphoma Receiving Chemotherapy: Assessment of Risk Factors.

Shyam Teegala, MD, Xiao Zhou, MD, PhD, Auris Huen, PHARMD, Yuan Ji, PhD, Luis Fayad, M.D., Jorge Enrique Romaguera, M.D., F.B. Hagemeister, M.D., Saroj Vadhan-Raj, M.D.

Blood (2006) 108 (11): 4103.

https://doi.org/10.1182/blood.V108.11.4103.4103

Published: 2006

Journal Articles

Incidence and Risk Factors for Severe Thrombocytopenia in Lymphoma Patients Receiving Chemotherapy.

Auris Huen, PharmD, Xiao Zhou, MD, PhD, Shyam Teegala, M.D., Yuan Ji, PhD, Luis Fayad, M.D., Jorge Enrique Romaguera, M.D., F.B. Hagemeister, M.D., Saroj Vadhan-Raj, M.D.

Blood (2006) 108 (11): 3994.

https://doi.org/10.1182/blood.V108.11.3994.3994

Published: 2006

NARROW

The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines

Safety and Efficacy of the Novel Combination of Panobinostat (LBH589) and Everolimus (RAD001) in Relapsed/Refractory Hodgkin and Non-Hodgkin Lymphoma,

Combined Inhibition of Janus and Aurora Kinases by the Novel Small Molecule Inhibitor AZD1480 Induces Cell Death and Downregulates PD-L1 and PD-L2 Expression In Hodgkin Lymphoma

Inhibition of Tak-1 by AZ-Tak1 Impairs NF-κB Activation, Downregulates XIAP and Activates Caspase-9 Inducing Apoptosis In Mantle Cell lymphoma

Phase I/II Study of the Novel Combination of Panobinostat (LBH589) and Everolimus (RAD001) In Relapsed/Refractory Hodgkin and Non-Hodgkin Lymphoma

A Phase I Study of Bortezomib in Combination with ICE (BICE) in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma

Higher Incidence of Venous Thromboembolism Is Associated with Initial Cycles of Chemotherapy in Lymphoma Patients: Creatinine and Hemoglobin as Key Risk Factors.

Safety and Efficacy of Bortezomib Plus ICE (BICE) for the Treatment of Relapsed/Refractory Classical Hodgkin’s Lymphoma.

High Incidence of Venous Thromboembolism in Patients with Lymphoma Receiving Chemotherapy: Assessment of Risk Factors.

Incidence and Risk Factors for Severe Thrombocytopenia in Lymphoma Patients Receiving Chemotherapy.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only